Point72 Ventures, an early-stage venture capital firm, has launched a new investment team focused on Healthcare.
Led by seasoned investor Scott Barclay, Point72 Ventures’ new Healthcare team will invest globally in early-stage founders trying to impact healthcare at scale.
Matthew Granade, Managing Partner, Point72 Ventures
Barclay has deep expertise in healthcare and the commercialization and scale of deep tech startups rooted in scientific advances and high-tech engineering innovation. Prior to joining Point72 Ventures, Barclay was a Partner at Data Collective Venture Capital (DCVC), where he created and led the Computational Care practice that focused on backing companies pushing compute into healthcare. He invested in and served on the boards of numerous DCVC portfolio companies, including Carbon Health, Medical Informatics Corp and Freenome, to name a few. Prior to joining DCVC, Barclay led operational and innovation teams at CVS Health, served as Chief Strategy and Product Officer of Surescripts, served as a consultant at The Boston Consulting Group, and established the capital markets desk in London for Montgomery Securities (later Bank of America Securities).
Point72 Ventures is a global venture capital firm that invests primarily in Fintech, AI/ML, Enterprise and Healthcare technologies.
The creation of the Healthcare investment platform represents another milestone in the firm’s focus on backing early-stage companies catalyzing key changes in the global economy. Since launching in 2016, the firm has invested in more than 50 companies across the Financial Services, Artificial Intelligence and Enterprise Technology verticals.
As an independent arm of Point72, the global asset management firm led by Steven A. Cohen, Point72 Ventures offices in New York City, Palo Alto, California, and Stamford, Connecticut.